Logullo Patricia, MacCarthy Angela, Kirtley Shona, Bullock Garrett S, Dhiman Paula, Ma Jie, Collins Gary S
Centre for Statistics in Medicine, UK EQUATOR Centre, Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences, University of Oxford, Oxford UK.
Department of Orthopaedic Surgery, Wake Forest School of Medicine, Winston-Salem, NC, USA.
J Clin Epidemiol. 2025 Jun 30;185:111893. doi: 10.1016/j.jclinepi.2025.111893.
To evaluate the quality of open peer review reports published alongside articles of randomized controlled trials (RCTs) in oncology.
We searched and sampled from completed parallel RCT articles published in 2021 in 62 BioMed Central journals operating open peer review and evaluated their first-round peer review report. We assessed and described the peer review report content, clarity, and completeness and explored whether reviewers commented on the manuscript's importance, robustness, interpretation, discussion of results, and RCT reporting. Two investigators evaluated the review reports independently, with conflict resolution involving a third author.
We sampled 26 RCTs and evaluated their 59 first peer review reports. Median word count was 276 (range = 0-1047). Only 11 reports were constructive (19%), suggesting solutions for the problems noted. Of reviewers commenting on the manuscript's methods section (n = 46/59, 78%), 74% (n = 34/46) addressed the suitability of the methodology. Fewer commented on the adequacy of conclusions (n = 15/59; 25%) or the applicability of results (n = 5/59; 9%), or whether study limitations had been acknowledged by authors (n = 11/59; 18%). Only four (7%) commented on open research practices, including deviations from protocols, completeness of reporting, and sharing of data and materials.
Peer review reports of published RCTs in oncology were short, superficial, and rarely constructive. Although there is indication that reviewers commented on study methodology, little attention was paid to study conclusions, deviation from study protocols, completeness of reporting, or data availability. Such review reports would be of limited value to authors for improving their trial study manuscripts, or to editors in deciding on manuscript publication.
Clinical trials are research studies that test whether a treatment or action works to help prevent or treat a disease. The results from these studies are important because they help doctors and policy makers decide what care is best for patients. Before the results from a clinical trial are published, other experts, sometimes including members of the public, carefully check the study to make sure it was conducted properly and that the results are trustworthy. This checking process is called "peer review". Reviewers look at things like how the study was carried out, whether the results make sense, and if the conclusions are fair. In our project, we looked at how well this peer review process worked in a selection of medical journals that make their review reports public. We read the reviews for 26 published trials to see what the reviewers said. We found that most of the review reports were very short and did not provide much detail to help the journal editors decide if the study should be published. Some reviews were only one sentence long. Many reviewers did not comment much on how the study was analyzed, and very few said whether the study conclusions were reasonable. Although peer review is supposed to help make sure research is reliable, we found that sometimes the reviews are too brief to be very helpful.
评估肿瘤学领域随机对照试验(RCT)文章所发表的开放式同行评议报告的质量。
我们从2021年发表在62种采用开放式同行评议的生物医学中心期刊上的已完成平行RCT文章中进行检索和抽样,并评估其第一轮同行评议报告。我们评估并描述了同行评议报告的内容、清晰度和完整性,并探讨了审稿人是否对手稿的重要性、稳健性、解释、结果讨论以及RCT报告进行了评论。两名研究人员独立评估这些评议报告,如有分歧则由第三位作者解决。
我们抽取了26项RCT,并评估了它们的59份首轮同行评议报告。中位数字数为276(范围 = 0 - 1047)。只有11份报告具有建设性(19%),针对所指出的问题提出了解决方案。在对稿件方法部分发表评论的审稿人中(n = 46/59,78%),74%(n = 34/46)讨论了方法的适用性。较少有人评论结论的充分性(n = 15/59;25%)或结果的适用性(n = 5/59;9%),或者作者是否承认研究的局限性(n = 11/59;18%)。只有4人(7%)对开放研究实践发表了评论,包括与方案的偏差、报告的完整性以及数据和材料的共享。
肿瘤学领域已发表RCT的同行评议报告简短、肤浅,很少具有建设性。尽管有迹象表明审稿人对研究方法进行了评论,但对研究结论、与研究方案的偏差、报告的完整性或数据可用性关注甚少。这样的评议报告对于作者改进其试验研究稿件或编辑决定稿件发表的价值有限。
临床试验是测试一种治疗方法或行动是否有助于预防或治疗疾病的研究。这些研究的结果很重要,因为它们帮助医生和政策制定者决定何种治疗对患者最有益。在临床试验结果发表之前,其他专家,有时包括公众成员,会仔细检查该研究,以确保其进行得当且结果可信。这个检查过程称为“同行评议”。审稿人会查看研究的开展方式、结果是否合理以及结论是否公正等方面。在我们的项目中,我们研究了在一些公开其评议报告的医学期刊中,这种同行评议过程的运作情况。我们阅读了26项已发表试验的评议,以了解审稿人说了什么。我们发现大多数评议报告非常简短,没有提供太多细节以帮助期刊编辑决定该研究是否应发表。有些评议只有一句话长。许多审稿人对研究的分析方式评论不多,很少有人提及研究结论是否合理。尽管同行评议旨在确保研究可靠,但我们发现有时评议过于简短而帮助不大。